MedPath

Blueberry Consumption and Type 2 Diabetes

Not Applicable
Completed
Conditions
Type2 Diabetes
Registration Number
NCT02972996
Lead Sponsor
Albany Research Institute, Inc.
Brief Summary

Lifestyle strategies that include dietary modification, such as consumption of a plant-based diet, are well recognized in disease prevention and may improve type 2 diabetes. Various components of a plant-based diet may contribute to its beneficial health effects, but there has been keen interest in the possibility that plant polyphenols may have a role. Blueberries are dietary sources of polyphenols, specifically anthocyanins. To date there are few human clinical trials evaluating the beneficial health effects of blueberries in populations with type 2 diabetes. The objective of the study is to determine if freeze-dried blueberries compared to a blueberry placebo will improve cardiometabolic parameters in men with type 2 diabetes.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
55
Inclusion Criteria
  • Male
  • Ages 45 to 75 years at beginning of study
  • BMI >25 kg/m2
  • HbA1C > 6.5 and < 9
  • Medical diagnosis of type 2 diabetes for at least 6 months
Exclusion Criteria
  • Use of insulin
  • Presence of chronic kidney disease (GFR < 45 mL/min), liver cirrhosis, gastrointestinal disease, pancreatic disease, or malabsorption syndromes
  • Weight loss of >10% of body weight over the last 6 months; routine participation in heavy exercise
  • Heavy smokers (>20 cigarettes per day)
  • Unable or unwilling to give informed consent or communicate with study staff
  • Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigators may interfere with study participation or the ability to follow the intervention protocol
  • Allergies to blueberries or blueberry products

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Blood Pressure8 weeks

Systolic blood pressure and diastolic blood pressure.

Secondary Outcome Measures
NameTimeMethod
Hemoglobin A1C8 weeks

Hemoglobin A1C is a surrogate marker of glycemic control over the preceding 2-3 months.

Trial Locations

Locations (1)

Stratton V.A. Medical Center

🇺🇸

Albany, New York, United States

Stratton V.A. Medical Center
🇺🇸Albany, New York, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.